Back | Next |
home / stock / rtrx / rtrx message board
Subject | By | Source | When |
---|---|---|---|
Price target raised $48: | dennisb | investorshub | 04/26/2015 6:11:53 PM |
Company of the Year:$$$$$$ | dennisb | investorshub | 04/11/2015 4:44:29 AM |
Strength is coming just upgraded $31 | dennisb | investorshub | 03/30/2015 5:38:10 PM |
We need to see more strength... | miilliondollarman | investorshub | 03/25/2015 6:21:17 AM |
stock of 2015:$$$$$$$ | dennisb | investorshub | 03/24/2015 3:16:36 PM |
The Game changer:$$$$ | dennisb | investorshub | 03/19/2015 5:11:53 PM |
Well, guys that it for me for now. | bullrider2 | investorshub | 03/18/2015 1:21:27 PM |
Lets see im on standbye on this 1... | GreenpandaXO | investorshub | 03/18/2015 1:12:16 PM |
$25-$30 in the cards?? | KingDMC | investorshub | 03/18/2015 12:53:04 PM |
Moving up$$$ | dennisb | investorshub | 01/14/2015 11:15:07 PM |
Looks like we're headed up 2015$$$$ | dennisb | investorshub | 12/22/2014 9:10:03 PM |
$RTRX DD Notes ~ http://www.ddnotesmaker.com/RTRX | stocktrademan | investorshub | 12/17/2014 3:52:19 PM |
Former $CEO is a con man: #msg-108504758. | DewDiligence | investorshub | 11/25/2014 6:05:31 PM |
J.- Posting to you here because I gave | oldberkeley | investorshub | 10/15/2014 1:42:29 PM |
You know there will be an investigation and | expediter13 | investorshub | 10/02/2014 2:37:51 PM |
Thanks for info: | dennisb | investorshub | 10/01/2014 2:09:14 AM |
CEO fired: #msg-106761489. | DewDiligence | investorshub | 09/30/2014 9:12:06 PM |
Looking Great!!! Up we Go: | dennisb | investorshub | 09/02/2014 4:38:13 PM |
Anybody alive out: stock looks strong looks like | dennisb | investorshub | 08/08/2014 10:23:08 PM |
Anybody alive out there on the News. Anything | dennisb | investorshub | 07/14/2014 4:11:21 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...